Spyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. GOOGL
6. APGE
7. DFTX
8. MU
9. IBM
10. HOOD

Go back to Spyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA
(NASDAQ: SYRE) Delayed: 100.32 +11.98 (13.56%)
Previous Close $88.34    52 Week High $ 
Open $95.00    52 Week Low $ 
Day High $101.71    P/E N/A 
Day Low $95.00    EPS $ 
Volume 2,804,957